Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Ronald Blue Trust Inc.

Posted by on Mar 26th, 2023

Ronald Blue Trust Inc. lifted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 119.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 510 shares of the medical research company’s stock after buying an additional 278 shares during the quarter. Ronald Blue Trust Inc.’s holdings in Bio-Rad Laboratories were worth $213,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Private Trust Co. NA grew its holdings in Bio-Rad Laboratories by 230.0% during the 3rd quarter. Private Trust Co. NA now owns 66 shares of the medical research company’s stock worth $28,000 after acquiring an additional 46 shares in the last quarter. Atlas Capital Advisors LLC bought a new position in shares of Bio-Rad Laboratories during the second quarter worth about $50,000. Allworth Financial LP grew its stake in Bio-Rad Laboratories by 414.8% in the third quarter. Allworth Financial LP now owns 139 shares of the medical research company’s stock worth $58,000 after purchasing an additional 112 shares in the last quarter. Quantbot Technologies LP bought a new stake in Bio-Rad Laboratories in the third quarter valued at about $62,000. Finally, Wipfli Financial Advisors LLC acquired a new stake in Bio-Rad Laboratories during the third quarter valued at approximately $82,000. Institutional investors own 64.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BIO. TheStreet upgraded Bio-Rad Laboratories from a “d+” rating to a “c” rating in a report on Thursday, February 16th. StockNews.com started coverage on shares of Bio-Rad Laboratories in a research note on Thursday, March 16th. They set a “buy” rating for the company. Credit Suisse Group raised their price target on shares of Bio-Rad Laboratories from $640.00 to $680.00 and gave the stock an “outperform” rating in a research report on Friday, February 17th. Finally, Royal Bank of Canada lifted their price target on shares of Bio-Rad Laboratories from $571.00 to $579.00 and gave the company an “outperform” rating in a report on Friday, February 17th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Bio-Rad Laboratories presently has an average rating of “Buy” and an average target price of $664.75.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP Timothy S. Ernst sold 1,746 shares of the business’s stock in a transaction that occurred on Wednesday, March 8th. The stock was sold at an average price of $486.43, for a total transaction of $849,306.78. Following the completion of the transaction, the executive vice president now directly owns 2,671 shares in the company, valued at $1,299,254.53. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 27.40% of the stock is owned by company insiders.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO opened at $460.78 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 5.55 and a quick ratio of 4.29. The firm has a market capitalization of $13.64 billion, a PE ratio of -3.79 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a 1-year low of $344.63 and a 1-year high of $607.54. The business’s fifty day moving average price is $473.30 and its two-hundred day moving average price is $436.37.

Bio-Rad Laboratories (NYSE:BIO – Get Rating) last released its quarterly earnings data on Thursday, February 16th. The medical research company reported $3.31 earnings per share for the quarter, missing analysts’ consensus estimates of $3.45 by ($0.14). The firm had revenue of $730.29 million during the quarter, compared to analyst estimates of $741.01 million. Bio-Rad Laboratories had a positive return on equity of 4.59% and a negative net margin of 129.66%. The firm’s revenue was down .3% on a year-over-year basis. During the same period last year, the business earned $3.21 EPS. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 15.91 EPS for the current year.

Bio-Rad Laboratories Company Profile

(Get Rating)

Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.

Featured Stories

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.